Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA - Get Free Report) was the recipient of a large decline in short interest during the month of May. As of May 31st, there was short interest totalling 2,000 shares, a decline of 31.0% from the May 15th total of 2,900 shares. Based on an average daily volume of 18,900 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.0% of the company's shares are short sold.
Genenta Science Stock Down 1.2%
Shares of Genenta Science stock traded down $0.04 during trading on Friday, reaching $3.07. 6,574 shares of the company were exchanged, compared to its average volume of 15,158. The business has a 50-day moving average price of $4.08 and a 200-day moving average price of $4.19. Genenta Science has a twelve month low of $2.79 and a twelve month high of $7.28.
Institutional Investors Weigh In On Genenta Science
Several large investors have recently modified their holdings of GNTA. Allianz SE grew its stake in shares of Genenta Science by 126.2% during the 1st quarter. Allianz SE now owns 233,550 shares of the company's stock worth $927,000 after acquiring an additional 130,300 shares in the last quarter. Algebris UK Ltd grew its position in Genenta Science by 122.2% in the first quarter. Algebris UK Ltd now owns 100,000 shares of the company's stock valued at $368,000 after purchasing an additional 55,000 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new stake in Genenta Science in the 4th quarter valued at $46,000. 15.13% of the stock is currently owned by institutional investors.
About Genenta Science
(
Get Free Report)
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.
Further Reading
Before you consider Genenta Science, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genenta Science wasn't on the list.
While Genenta Science currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
